✦ LIBER ✦

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial

✍ Scribed by Ambrosy, Andrew P.; Vaduganathan, Muthiah; Mentz, Robert J.; Greene, Stephen J.; Subačius, Haris; Konstam, Marvin A.; Maggioni, Aldo P.; Swedberg, Karl; Gheorghiade, Mihai

Book ID: 123042972
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 704 KB
Volume: 165
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2012.11.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Diuretic Resistance and Clinical Outcome

Diuretic Resistance and Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Trial

✍ Mecklai, Alicia; Subacius, Haris; Katz, Stuart 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 216 KB

Gender Does Not Affect Postdischarge Out

Gender Does Not Affect Postdischarge Outcomes in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan [EVEREST] Trial)

✍ Ami N. Shah; Robert J. Mentz; Mihai Gheorghiade; Mary J. Kwasny; Angela J. Fough 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 360 KB

Causes of death and rehospitalization in

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

✍ Christopher M. O'Connor; Alan B. Miller; John E.A. Blair; Marvin A. Konstam; Pat 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 267 KB

Prognostic Value of Monocyte Count in Pa

Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial)

✍ Stephen J. Greene; Matthew E. Harinstein; Muthiah Vaduganathan; Haris Subačius; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 368 KB

Continental Differences in Clinical Char

Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure: Results From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Program

✍ John E.A. Blair; Faiez Zannad; Marvin A. Konstam; Thomas Cook; Brian Traver; Joh 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 494 KB

Effects of tolvaptan on physician-assess

Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials

✍ Peter S. Pang; Mihai Gheorghiade; Jamil Dihu; Karl Swedberg; Sadiya Khan; Aldo P 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 163 KB